Last reviewed · How we verify

NCT05829135

Improving Glare and Visual Comfort for Patients With Visual Impairment

Withdrawn NA Last updated 19 June 2025
What this trial tests

NA trial testing Acuvue Oasys with Transitions in Photophobia. Withdrawn.

Timeline
1 May 2023
Primary endpoint
16 June 2025
16 June 2025

Quick facts

Lead sponsorNova Southeastern University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 May 2023
Primary completion16 June 2025
Estimated completion16 June 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Nova Southeastern University

Who can join

Adults 18 to 64, any sex, with Photophobia or Visual Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the use of contact lenses with transitions technology to improve glare, light sensitivity and overall visual comfort in patients with visual impairment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Photophobia

Currently open trials in the same condition.

Other Nova Southeastern University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05829135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing